Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE MEASUREMENTS (Tables)

v3.21.2
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS

 SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS

    As of September 30, 2021     Fair Value Measurements  
    Carrying     Fair     As of September 30, 2021  
    Amount     Value     Level 1     Level 2     Level 3  
              (unaudited)              
Liabilities:                              
Contingent consideration:                                        
Asuragen (1)   $ 2,136     $ 2,136     $       -     $ -     $ 2,136  
Other long-term liabilities:                                        
Warrant liability (2)     158       158       -       -       158  
    $ 2,294     $ 2,294     $ -     $ -     $ 2,294  

 

    As of December 31, 2020     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2020  
    Amount     Value     Level 1     Level 2     Level 3  
                               
Liabilities:                                        
Contingent consideration:                                        
Asuragen (1)   $ 2,216     $ 2,216     $ -     $ -     $ 2,216  
Other long-term liabilities:                                        
Warrant liability (2)     21       21       -       -       21  
    $ 2,237     $ 2,237     $ -     $ -     $ 2,237  

 

(1)(2) See Note 9, Accrued Expenses and Long-Term Liabilities 

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to September 30, 2021 is as follows:

 SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

                     

Cancellation

of Obligation/

   

Adjustment

 to Fair Value/

       
    December 31, 2020     Payments     Accretion     Conversions Exercises     Mark to Market     September 30,
2021
 
    (unaudited)  
Contingent consideration liability   $ 2,216     $ (398 )   $ 375     $       -     $ (57 )   $ 2,136  
                                                 
Underwriters Warrants     21       -       -       -       137       158  
    $ 2,237     $ (398 )   $ 375     $ -     $ 80     $ 2,294